Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Covington
US Department of Justice
UBS
Novartis
Daiichi Sankyo
Deloitte
Argus Health
US Army
QuintilesIMS

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,784,869

« Back to Dashboard

Which drugs does patent 8,784,869 protect, and when does it expire?


Patent 8,784,869 protects NATESTO and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 8,784,869

Title:Controlled release delivery system for nasal applications and methods of treatment
Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Inventor(s): Mattern; Claudia (Stans, CH)
Assignee: Mattern Pharma AG (Vaduz, LI)
Application Number:13/547,774
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Aytu Bioscience Inc
NATESTO
testosterone
GEL, METERED;NASAL205488-001May 28, 2014RXNoNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,784,869

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03025769Nov 11, 2003

Non-Orange Book Patents for Patent: 8,784,869

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,238,072Controlled release delivery system for nasal applications and method of treatment► Subscribe
2,014,073,618► Subscribe
8,784,882Controlled release delivery system for nasal applications and method of treatment► Subscribe
8,877,230Controlled release delivery system for nasal applications► Subscribe
9,579,280Controlled release delivery system for nasal applications and method of treatment► Subscribe
8,574,622Controlled release delivery system for nasal applications► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,784,869

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina047722► Subscribe
Austria319426► Subscribe
Australia2004286781► Subscribe
BrazilPI0416370► Subscribe
Canada2541498► Subscribe
Germany60303854► Subscribe
Denmark1530965► Subscribe
European Patent Office1530965► Subscribe
Spain2258694► Subscribe
CroatiaP20060147► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Farmers Insurance
Cipla
Johnson and Johnson
Novartis
Argus Health
Queensland Health
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot